We are building Context Therapeutics to become a global company that will discover, develop and market groundbreaking cancer treatments to patients around the world, eliminating the fear that comes with a cancer diagnosis.
ONWARD are clinical research studies for patients with metastatic cancer who are progesterone receptor positive (PR+).
Progesterone receptor evaluation is typically performed during initial biopsy evaluation. At this time, PR status is determined as well as other cancer subtypes, including estrogen receptor (ER) and HER2.
Yes. Apristor, has already been given to patients in previous studies. So far, 88 patients with different types of cancers have received Apristor. Additionally, several hundred women have received onapristone, the immediate release version of Apristor, in previous studies evaluating the drug's potential in breast cancer as well as a contraceptive.
The investigational drug Apristor is administered as a pill. The drug functions by preventing progesterone from binding to the progesterone receptor. Context Therapeutics, the company who is studying Apristor, believes the drug may halt the growth of cancer cancer cells by preventing progesterone receptor from activating pro-survival pathways in PR+ tumors.
Patients take two 50 mg pills of Apristor in 12 hour intervals with or without food.